Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis

The programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway plays a crucial role in the immune escape mechanism and growth of cancer cells in endometrial cancer (EC). Clinical trials investigating PD-1/PD-L1 inhibitor have shown promising results in other cancers, but t...

Full description

Bibliographic Details
Main Authors: Mohd Nazzary Mamat @ Yusof, Kah Teik Chew, Abdul Muzhill Hannaan Abdul Hafizz, Siti Hajar Abd Azman, Wira Sofran Ab Razak, Muhammad Rafi’uddin Hamizan, Nirmala Chandralega Kampan, Mohamad Nasir Shafiee
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
endometrial cancer
programmed cell death protein 1
programmed cell death ligand 1
programmed cell death ligand 2
immune checkpoint inhibitor
mismatch repair
Online Access:https://www.mdpi.com/2072-6694/15/16/4032

Internet

https://www.mdpi.com/2072-6694/15/16/4032

Similar Items